Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells

被引:15
|
作者
Arlanov, Rudolf [1 ,2 ]
Porter, Andrew [3 ]
Strand, Dennis [4 ]
Brough, Rachel [3 ]
Karpova, Darja [2 ]
Kerb, Reinhold [1 ]
Wojnowski, Leszek [2 ]
Schwab, Matthias [1 ,5 ]
Lang, Thomas [1 ]
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[2] Johannes Gutenberg Univ Mainz, Inst Pharmacol, Mainz, Germany
[3] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Haematol, Gene Targeting Grp, London, England
[4] Johannes Gutenberg Univ Mainz, Dept Med 1, D-6500 Mainz, Germany
[5] Univ Tubingen Hosp, Inst Expt & Clin Pharmacol & Toxicol, Dept Clin Pharmacol, Tubingen, Germany
关键词
ABC transporter; ABCC2; MRP2; pharmacogenetics; Screen and Insert; DUBIN-JOHNSON-SYNDROME; RESISTANCE-ASSOCIATED PROTEIN-2; REGULATED TRANSGENE EXPRESSION; ORGANIC ANION TRANSPORTER; GENETIC POLYMORPHISMS; DRUG TRANSPORTER; LIVER-INJURY; MRP2; ABCC2; ASSOCIATION; MUTATION;
D O I
10.1002/humu.22041
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The multidrug resistance-associated protein 2 (MRP2/ABCC2) is involved in the efflux of endogenous and xenobiotic substrates, including several anticancer and antiviral drugs. The functional consequences of ABCC2 protein variants remain inconsistent, which may be due to shortcomings of the in vitro assays used. To study systematically the functional consequences of nonsynonymous ABCC2 variants, we used a novel Screen and Insert (ScIn) technology to achieve stable and highly reproducible expression of 13 ABCC2 variants in HT1080 cells. Western blotting revealed lower (3065%) ABCC2 expression for D333G, R1174H, and R1181L as compared with wild type (WT; 100%), whereas the linked variant V1188E/C1515Y resulted in higher expression (150%). R1174H caused mislocalization of ABCC2 to the cytoplasm with an endoplasmic reticulum-like distribution. Variants N1244K and R1174H decreased transport of glutathionemethylfluorescein (GSMF) and glutathionemonochlorobimane (GSMCB) by 80% and 50%, respectively, whereas R1181L and P1291L reduced only GSMCB transport by 50% as compared with WT. Contrary to protein data, the double variant V1188E/C1515Y decreased specific transport activity for GSMF and GSMCB by 40%. The ScIn approach is a feasible and reliable method to functionally characterize systematically ABCC2 variants. D333G, R1174H, R1181L, N1244K, P1291L, and double variant V1188E/C1515Y have been identified as most promising for further clinical evaluation. Hum Mutat 33:750762, 2012. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:750 / 762
页数:13
相关论文
共 22 条
  • [1] Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression
    Nguyen, T. D.
    Markova, S.
    Liu, W.
    Gow, J. M.
    Baldwin, R. M.
    Habashian, M.
    Relling, M. V.
    Ratain, M. J.
    Kroetz, D. L.
    PHARMACOGENOMICS JOURNAL, 2013, 13 (05): : 396 - 402
  • [2] Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2)
    Megaraj, Vandana
    Zhao, Tianyong
    Paumi, Christian M.
    Gerk, Phillip M.
    Kim, Richard B.
    Vore, Mary
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (08): : 506 - 515
  • [3] Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression
    T D Nguyen
    S Markova
    W Liu
    J M Gow
    R M Baldwin
    M Habashian
    M V Relling
    M J Ratain
    D L Kroetz
    The Pharmacogenomics Journal, 2013, 13 : 396 - 402
  • [4] In silico and biological analyses of missense variants of the human biliary efflux transporter ABCC2: effects of novel rare missense variants
    Koelz, Charlotte
    Gaugaz, Fabienne Z.
    Handin, Niklas
    Schaeffeler, Elke
    Tremmel, Roman
    Winter, Stefan
    Klein, Kathrin
    Zanger, Ulrich M.
    Artursson, Per
    Schwab, Matthias
    Nies, Anne T.
    BRITISH JOURNAL OF PHARMACOLOGY, 2024, 181 (22) : 4593 - 4609
  • [5] Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2)
    Qadri, Ishtiaq
    Hu, Ling-Jia
    Iwahashi, Mieko
    Al-Zuabi, Subhi
    Quattrochi, Linda C.
    Simon, Francis R.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2009, 234 (03) : 281 - 292
  • [6] Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2
    Masakazu Hirouchi
    Hiroshi Suzuki
    Masaya Itoda
    Shogo Ozawa
    Jun-ichi Sawada
    Ichiro Ieiri
    Kenji Ohtsubo
    Yuichi Sugiyama
    Pharmaceutical Research, 2004, 21 : 742 - 748
  • [7] Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2
    Hirouchi, M
    Suzuki, H
    Itoda, M
    Ozawa, S
    Sawada, J
    Ieiri, I
    Ohtsubo, K
    Sugiyama, Y
    PHARMACEUTICAL RESEARCH, 2004, 21 (05) : 742 - 748
  • [8] Mutation and functional analysis of ABCC2/multidrug resistance protein 2 in a Japanese patient with Dubin-Johnson syndrome
    Uchiumi, Takeshi
    Tanamachi, Hiroyuki
    Kuchiwaki, Kajiyo
    Kajita, Mitsuharu
    Matsumoto, Shinya
    Yagi, Mikako
    Kanki, Tomotake
    Kang, Dongchon
    HEPATOLOGY RESEARCH, 2013, 43 (05) : 569 - 575
  • [9] Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics
    Niemi, Mikko
    Arnold, Katja A.
    Backman, Janne T.
    Pasanen, Marja K.
    Goedtel-Armbrust, Ute
    Wojnowski, Leszek
    Zanger, Ulrich M.
    Neuvonen, Pertti J.
    Eichelbaum, Michel
    Kivisto, Kari T.
    Lang, Thomas
    PHARMACOGENETICS AND GENOMICS, 2006, 16 (11): : 801 - 808
  • [10] Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: Involvement of SREBP-mediated gene regulation
    Kobayashi, Masaki
    Gouda, Keisuke
    Chisaki, Ikumi
    Asada, Koji
    Ogura, Jiro
    Takahashi, Natsuko
    Konishi, Toru
    Koshida, Yusuke
    Sasaki, Shotaro
    Yamaguchi, Hiroaki
    Iseki, Ken
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 452 (1-2) : 36 - 41